Clinical trials: Kidney Insufficiency
End Stage Renal Disease
Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode
The study investigates the performance of a new dialyzer (Theranova 400) containing a membrane with increased pore sizes. The performance will be determined by the removal of middle molecules (with different molecular size) from…
- Trial name
- NCT02377622
- Testing
- THERANOVA 400 dialyzer prototype AA, THERANOVA 400 dialyzer prototype BB, FX CorDiax 80 Dialyzer
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Vantive Health LLC
T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease.
- Trial name
- GLOW-CKD (NCT07116928)
- Testing
- ganagliflozin
- Where
- China
- Volunteers
- 1,244 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Anemia, Chronic Kidney Disease
Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease
The purpose of this study is to evaluate the ability of peginesatide (AF37702) to increase and maintain increased hemoglobin levels in participants with chronic kidney disease (CKD) (either not on dialysis, receiving regular…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure, Pure Red Cell Aplasia
- Trial name
- NCT00314795
- Testing
- Peginesatide
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 22 people
- Sponsor
- Takeda
Kidney Dysfunction
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function
This is a single center, open-label, non-randomized, 1:1 parallel control and single dose administration study design. Healthy subjects will be matched to severe renal function impaired (eGFR≤30mL/min/1.73m2，CKD-EPI estimated)…
- Trial name
- NCT02840812
- Testing
- Nemonoxacin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zhejiang Medicine Co., Ltd.
Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)
A Phase 4, 52 week, single arm, multicentre post marketing surveillance to evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease (CKD)
- Trial name
- NCT05515367
- Testing
- Desidustat
- Where
- India
- Volunteers
- 1,004 people
- Sponsor
- Zydus Lifesciences Limited
Hepatic Impairment, Renal Impairment
A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of zibotentan in patients with moderate hepatic and moderate renal impairment in comparison to a matched healthy control group.
- Trial name
- NCT05112419
- Testing
- Zibotentan
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
End Stage Renal Disease, Peritoneal Dialysis-associated Peritonitis
A Prospective Clinical Study to Assess the Clinical Utility of Turbidity in Patients Using In-Home Peritoneal Dialysis
This study aims to determine if the CloudCath device can detect infections related to peritoneal dialysis (peritonitis) as fast or faster than the current standard methods used by patients and doctors to detect such infections.
- Conditions
- End Stage Renal Disease, Peritoneal Dialysis-associated Peritonitis, Peritonitis
- Trial name
- ACT (NCT05285436)
- Testing
- CloudCath System
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- CloudCath
Chronic Kidney Disease, Anemia, Iron-Deficiency
A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients
The purpose of this study is to determine the safety profile of iron oligosaccharide in patients with chronic kidney disease with a need for parenteral iron.
- Trial name
- NCT00536666
- Testing
- Iron oligosaccharide
- Where
- Denmark
- Volunteers
- 182 people
- Sponsor
- Pharmacosmos A/S
End Stage Renal Disease (ESRD)
Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine
Randomized, cross-over, controlled, open label study. The aim of this study is to demonstrate that glucose may completely be replaced by a combination of xylitol and carnitine in the bimodal PD solution for long dwell exchange.
- Trial name
- NCT04086212
- Testing
- Icodextrin, xylitol and carnitine solution for peritoneal dialysis, EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution
- Sponsor
- Iperboreal Pharma Srl
Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD)
SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data
This study is being carried out in 4 countries (France, Italy, Spain and the UK) to understand the clinical care pathway of population living with type 2 diabetes who also have evidence of chronic kidney disease.
- Trial name
- NCT06769646
- Testing
- No tretament given
- Where
- India
- Volunteers
- 110,074 people
- Sponsor
- Novo Nordisk A/S
Renal Insufficiency
Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment
This Phase 1 study is being conducted to evaluate the effect of severe renal impairment on the PK, safety and tolerability of Aztreonam-Avibactam.
- Trial name
- NCT04486625
- Testing
- Aztreonam-Avibactam
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer
Study of SHR6390 in Renal Insufficiency and Healthy Subjects
The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 24-30 subjects. Subjects will take the SHR6390 on Day1.
- Trial name
- NCT05515289
- Testing
- SHR6390
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Renal Impairment
To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment
This is a Phase 1, open label, single-dose, pharmacokinetic study to be conducted in male and female subjects with normal and impaired renal function.
- Trial name
- NCT02942810
- Testing
- WCK 5222
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Wockhardt
Chronic Renal Insufficiency, Diabete Mellitus
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus…
- Conditions
- Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
- Trial name
- NCT01252810
- Testing
- GE-145
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- GE Healthcare
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.
This study will assess the saftey of giving fluticasone furoate 200mcg/GW642444M 25mcg once daily for 7 days to patients with severe renal imparement.
- Trial name
- NCT01266980
- Testing
- Inhaled FF/ GW642444M (200/25mcg)
- Where
- Czechia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
End Stage Renal Disease, Thrombosis
Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
This study evaluates the safety and efficacy of AB023 (xisomab 3G3) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts.
- Trial name
- NCT03612856
- Testing
- AB023- Dose 1, AB023-Dose 2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Aronora, Inc.
Renal Anemia Associated With Chronic Renal Failure (CRF)
A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug
This study is to evaluate safety and efficacy of intermittent oral dosing of ASP1517 in dialysis chronic kidney disease patients with anemia.
- Trial name
- NCT01888445
- Testing
- roxadustat, darbepoetin alfa
- Where
- 8 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Astellas Pharma Inc
Diabetic Nephropathies
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
- Trial name
- NCT01200394
- Testing
- PF-00489791
- Where
- 160 sites in United States, Australia and 13 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Chronic Kidney Disease, Dialysis
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00506441
- Testing
- MCI-196
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 245 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.
- Trial name
- NCT07107945
- Testing
- Empagliflozin
- Where
- 93 sites in United States, Argentina and 16 more
- Volunteers
- 135 people
- Sponsor
- Boehringer Ingelheim